Omecamtiv mecarbil (OM)💊 is designed to treat #HeartFailure with reduced ejection fraction. OM increases cardiac contractility💪 by activating cardiac myosin. A trial found that OM improved cardiac function. Read more below! #biom4180 #clinicaltrial ht
Omecamtiv mecarbil (OM)💊 is designed to treat #HeartFailure with reduced ejection fraction. OM increases cardiac contractility💪 by activating cardiac myosin. A trial found that OM improved cardiac function. Read more below! #biom4180 #clinicaltrial ht
Omecamtiv mecarbil (OM)💊 is designed to treat #HeartFailure with reduced ejection fraction. OM increases cardiac contractility💪 by activating cardiac myosin. A trial found that OM improved cardiac function. Read more below! #biom4180 #clinicaltrial ht
Omecamtiv Mecarbil (OM)💊 is designed to treat🫀failure with reduced ejection fraction. OM increases cardiac contractility by activating cardiac myosin. A trial found that OM improved cardiac function. Read more below! #biom4180 #clinicaltrial https://t
Omecamtiv Mecarbil (OM)💊 is designed to treat 🫀 failure with reduced ejection fraction. OM increases cardiac contractility by activating cardiac myosin. A trial found that OM improved cardiac function. Read more below! #biom4180 #clinicaltrial https:/
RT @JACCJournals: "Omecamtiv Mecarbil in Chronic #HFrEF: Rationale and Design of GALACTIC-HF" was #JACCHF's #1 most talked about paper in 2…
RT @JACCJournals: "Omecamtiv Mecarbil in Chronic #HFrEF: Rationale and Design of GALACTIC-HF" was #JACCHF's #1 most talked about paper in 2…
RT @JACCJournals: "Omecamtiv Mecarbil in Chronic #HFrEF: Rationale and Design of GALACTIC-HF" was #JACCHF's #1 most talked about paper in 2…
"Omecamtiv Mecarbil in Chronic #HFrEF: Rationale and Design of GALACTIC-HF" was #JACCHF's #1 most talked about paper in 2020. Check out the paper and find the Altmetric attention score here: https://t.co/ycs3djoeOP #HeartFailure https://t.co/R2krG78Di5
RT @IccResidencia: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Frac... https://t.co/8zIEWZ6Vuz ¿Estamos ante la pres…
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Frac... https://t.co/8zIEWZ6Vuz ¿Estamos ante la prescencia del primer fármaco que mejora la contractilidad, en mejorar el pronóstico clínico de los pacientes con HFrFE? @EduardoPerna1 @jor
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction: ?? #GALACTIC_HF trial https://t.co/Cph6mMROG9 https://t.co/nSx1VHk2tn
RT @mvaduganathan: Many congrats to @jteerlinkmd, @MyosinMD, & investigators in successfully evaluating a novel compound with distinct MOA…
RT @mvaduganathan: Many congrats to @jteerlinkmd, @MyosinMD, & investigators in successfully evaluating a novel compound with distinct MOA…
RT @UoGHeartFailure: Results will presented @AHAMeetings Scientific sessions on Friday Nov 13th 10:35 C.D.T GALACTIC-HF design paper publi…
RT @mvaduganathan: Many congrats to @jteerlinkmd, @MyosinMD, & investigators in successfully evaluating a novel compound with distinct MOA…
Results will presented @AHAMeetings Scientific sessions on Friday Nov 13th 10:35 C.D.T GALACTIC-HF design paper published earlier this year in JACC-HF: https://t.co/uAPDWV1ghK Baseline characteristics paper available here: https://t.co/gOMNq6TG1g
Many congrats to @jteerlinkmd, @MyosinMD, & investigators in successfully evaluating a novel compound with distinct MOA in HF #GALACTICHF Registration https://t.co/2ykwMTN0Ez Design in @JACCJournals: https://t.co/vRG23x61dY Baseline in @escardio #EJ
RT @sarahhudsonuk: Possible future medication in #HF: omecamtiv mecarbil, a cardiac myosin activator.Presentation by @lamcardio at #ESCCong…
RT @sarahhudsonuk: Possible future medication in #HF: omecamtiv mecarbil, a cardiac myosin activator.Presentation by @lamcardio at #ESCCong…
RT @sarahhudsonuk: Possible future medication in #HF: omecamtiv mecarbil, a cardiac myosin activator.Presentation by @lamcardio at #ESCCong…
RT @sarahhudsonuk: Possible future medication in #HF: omecamtiv mecarbil, a cardiac myosin activator.Presentation by @lamcardio at #ESCCong…
RT @sarahhudsonuk: Possible future medication in #HF: omecamtiv mecarbil, a cardiac myosin activator.Presentation by @lamcardio at #ESCCong…
Possible future medication in #HF: omecamtiv mecarbil, a cardiac myosin activator.Presentation by @lamcardio at #ESCCongress covered COSMIC HF(reported) & GALACTIC HF(recruitment finished,not yet reported)trials. Exciting times! https://t.co/6VUJnqBj8
Looking forward to the results of this
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
Intéressent :3
@Terenard_Goc @coconnormd @JACCJournals Yes, we believe so! #COSMIC_HF demonstrated consistent benefits of omecamtiv mecarbil on increased stroke volume, decreased LV volumes & BNP in #HFrEF pts with both ischemic and non-ischemic cardiomyopathy. #GALA
RT @JACCJournals: New #JACCHF State-of-the-Art Review: Could this be a game changer in #heartfailure treatment? Check out the methods paper…
RT @coconnormd: The most important HF trial to report later this year
RT @coconnormd: The most important HF trial to report later this year
RT @coconnormd: The most important HF trial to report later this year https://t.co/lGYN2e7R16
RT @coconnormd: The most important HF trial to report later this year
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
Cool stuff coming down the pipeline.
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction https://t.co/sRNxf2lkan
RT @coconnormd: The most important HF trial to report later this year
RT @coconnormd: The most important HF trial to report later this year
RT @coconnormd: The most important HF trial to report later this year
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @coconnormd: The most important HF trial to report later this year
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @coconnormd: The most important HF trial to report later this year
RT @coconnormd: The most important HF trial to report later this year https://t.co/lGYN2e7R16
RT @coconnormd: The most important HF trial to report later this year
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @coconnormd: The most important HF trial to report later this year
RT @coconnormd: The most important HF trial to report later this year
RT @coconnormd: The most important HF trial to report later this year
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @coconnormd: The most important HF trial to report later this year
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @coconnormd: The most important HF trial to report later this year
RT @coconnormd: The most important HF trial to report later this year
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
The most important HF trial to report later this year
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
@ReddyNeeti @VijhaniPraveen
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
RT @JACCJournals: #JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an int…
#JACCHF state-of-the-art review: Dr. John Teerlink and colleagues discuss the rationale and design of #GALACTICHF, an international, multicenter trial observing the effect of omecamtiv mecarbil on outcomes in chronic #HFrEF patients. https://t.co/6OpQk5Uf1
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
RT @clarelmurphy: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure https://t.co/We0zDGLnPB
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
RT @clarelmurphy: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure https://t.co/We0zDGLnPB
RT @clarelmurphy: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure https://t.co/We0zDGLnPB
RT @clarelmurphy: Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure https://t.co/We0zDGLnPB
Omecamtiv Mecarbil in Chronic Heart Failure With Reduced Ejection Fraction | JACC: Heart Failure https://t.co/We0zDGLnPB
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…
RT @JonathanDavisHF: Exciting time for #HeartFailure #GDMTWorks: ARNI, SGLT2-I & ?vericiguat. Look forward to more data on Omecamtiv @jteer…